Lu KH - Search Results

1

Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer.

Hinchcliff EM, Knisely A, Adjei N, Fellman B, Yuan Y, Patel A, Xu C, Westin SN, Sood AK, Soliman PT, Shafer A, Fleming ND, Gershenson DM, Vikram R, Bathala T, Vining D, Ganeshan DM, Lu KH, Sun CC, Meyer LA, Jazaeri AA. Hinchcliff EM, et al. Among authors: lu kh. Cancer. 2024 Apr 1;130(7):1061-1071. doi: 10.1002/cncr.35126. Epub 2023 Nov 27. Cancer. 2024. PMID: 38009662 Clinical Trial.

2

Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential.

Crispens MA, Bodurka D, Deavers M, Lu K, Silva EG, Gershenson DM. Crispens MA, et al. Obstet Gynecol. 2002 Jan;99(1):3-10. doi: 10.1016/s0029-7844(01)01649-0. Obstet Gynecol. 2002. PMID: 11777502

3

Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma.

Jazaeri AA, Lu K, Schmandt R, Harris CP, Rao PH, Sotiriou C, Chandramouli GV, Gershenson DM, Liu ET. Jazaeri AA, et al. Mol Carcinog. 2003 Feb;36(2):53-9. doi: 10.1002/mc.10098. Mol Carcinog. 2003. PMID: 12557260

4

Grading ovarian serous carcinoma using a two-tier system.

Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG. Malpica A, et al. Am J Surg Pathol. 2004 Apr;28(4):496-504. doi: 10.1097/00000478-200404000-00009. Am J Surg Pathol. 2004. PMID: 15087669

5

An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients.

Vidal CI, Mintz PJ, Lu K, Ellis LM, Manenti L, Giavazzi R, Gershenson DM, Broaddus R, Liu J, Arap W, Pasqualini R. Vidal CI, et al. Oncogene. 2004 Nov 25;23(55):8859-67. doi: 10.1038/sj.onc.1208082. Oncogene. 2004. PMID: 15480432

6

Heterogeneity of stage IIIA endometrial carcinomas: implications for adjuvant therapy.

Slomovitz BM, Ramondetta LM, Lee CM, Oh JC, Eifel PJ, Jhingran A, Burke TW, Gershenson DM, Lu KH. Slomovitz BM, et al. Among authors: lu kh. Int J Gynecol Cancer. 2005 May-Jun;15(3):510-6. doi: 10.1111/j.1525-1438.2005.15317.x. Int J Gynecol Cancer. 2005. PMID: 15882178 Free article.

7

Correlation of cyclin D1 and cyclin D3 overexpression with the loss of PTEN expression in endometrial carcinoma.

Wu W, Slomovitz BM, Soliman PT, Schmeler KM, Celestino J, Milam MR, Lu KH. Wu W, et al. Among authors: lu kh. Int J Gynecol Cancer. 2006 Jul-Aug;16(4):1668-72. doi: 10.1111/j.1525-1438.2006.00642.x. Int J Gynecol Cancer. 2006. PMID: 16884382

8

Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.

Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B. Uyei A, et al. Cancer. 2006 Dec 15;107(12):2745-51. doi: 10.1002/cncr.22352. Cancer. 2006. PMID: 17109443 Free article.

9

Loss of phosphatase and tensin homologue deleted on chromosome 10 and phosphorylation of mammalian target of rapamycin are associated with progesterone refractory endometrial hyperplasia.

Milam MR, Soliman PT, Chung LH, Schmeler KM, Bassett RL Jr, Broaddus RR, Lu KH. Milam MR, et al. Among authors: lu kh. Int J Gynecol Cancer. 2008 Jan-Feb;18(1):146-51. doi: 10.1111/j.1525-1438.2007.00958.x. Epub 2007 Apr 26. Int J Gynecol Cancer. 2008. PMID: 17466036

10

Endometrial cancer associated with defective DNA mismatch repair.

Soliman PT, Lu K. Soliman PT, et al. Obstet Gynecol Clin North Am. 2007 Dec;34(4):701-15, viii. doi: 10.1016/j.ogc.2007.09.003. Obstet Gynecol Clin North Am. 2007. PMID: 18061865 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

778 results

Search Page